Valeant Pharmaceuticals International Inc. agreed to sell about $2.1 billion in assets as the embattled Canadian drugmaker seeks to streamline its businesses and ease its debt burden. L’Oreal SA will pay Valeant $1.3 billion for three skincare brands, the Paris-based company Tuesday said in a statement.